ESCMID Vaccines 2025
Read the full Report (pdf)
European Society of Clinical Microbiology and Infectious Diseases | Vaccines 10–13 September 2025 Lisbon, Portugal
Featured articles
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
ESCMID Vaccines 2025 Highlights Podcast
CONTENTS
Online First
Pneumococcal Vaccination
A quarter of US children have incomplete pneumococcal vaccination by age 2
V116 shows promise for adults at risk of pneumococcal disease
Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years
The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease
Influenza and COVID-19 Vaccination
Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals
Intranasal COVID-19 vaccine shows promising results in preclinical mouse models
Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season
Lower age is linked to reduced uptake of influenza and COVID-19 vaccination
RSV vaccination and Immunisation
Combination respiratory vaccines show promise but face key challenges
Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA
RSV immunisation: Maternal versus direct infant immunisation
European pregnant women show openness to maternal RSV vaccination
Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation
